Introduction {#S0001}
============

The use of antibiotics, first discovered approximately 80 years ago,[@CIT0001] is a double-edged sword[@CIT0002] Antibiotics play an extremely important role in the human against various bacterial and viral infections by killing pathogens directly, reducing tissue damage and inhibiting the production of pro-inflammatory cytokines. However, long-term antibiotic misuse induces the emergence of multidrug-resistant (MDR) bacteria[@CIT0003] Decreased antibiotic uptake, like reducing the entry of antibiotics into the bacteria and activating efflux system, and inactivation antibiotics targets are the most common resistance mechanism for bacterial. Frequently, ventilator-associated pneumonia (VAP) and intensive care unit (ICU) patients suffer lung bacterial pneumonia and are infected with multiple bacterial pathogens[@CIT0004] Among these, Gram-negative *P. aeruginosa* and *A. baumannii* are the worst MDR bacteria that generally affect individuals with bacterial pneumonia-induced morbidity and mortality, particularly opportunistic and cross-infected bacteria within long-term in-hospital respiratory medicine patients.[@CIT0005],[@CIT0006] *Staphylococcus aureus* alpha toxin (AT) has recently been identified as a risk factor for host mucosal defense and macrophage function. Coinfection with *S. aureus* expressing AT improves the dissemination and propagation of gram-negative bacteria, such as *Pseudomonas aeruginosa, Klebsiella pneumoniae*, and *Acinetobacter baumannii*[@CIT0007] No drugs can effectively eliminate and clear MDR bacteria. Therefore, therapeutic strategies for MDR bacterial coinfection remain to be elucidated.

Antimicrobial peptides (AMPs), which are widely present in a range of organisms, exhibit a variety of biological activities, including antibacterial,[@CIT0004],[@CIT0008],[@CIT0009] antifungal,[@CIT0010] antiparasitic,[@CIT0011] antiviral,[@CIT0012] and anticancer[@CIT0013] activities. Generally, AMPs are distinguished into four structural classes: α-helical peptides, β-sheet peptides, extended peptides, and loop peptides,[@CIT0014]--[@CIT0017] of which α-helical peptides represent the largest proportion of the AMPs that have been found. β-Sheet peptides are also widely studied, because of their intramolecular disulfide bond-mediated rigidity in aqueous solution. *Tachyplesin III*, a β-sheet AMP,[@CIT0018] not only shows potential activity against MDR bacterial infection but also exhibits low cytotoxicity to mammalian cells[@CIT0019] The cationic β-hairpin structure of *Tachyplesin III* provides strong stability under serum conditions and provides the foundation for bacteria killing by directly interacting with lipid membranes[@CIT0020] or binding to bacterial DNA[@CIT0021] Recently, our group reported a novel mechanism by which *Tachyplesin III* may target FabG in bacteria killing[@CIT0009]

Except the capability of AMPs killing bacterial directly, AMPs also show potential role in innate immune cell regulation[@CIT0016] *Cathelicidin-BF*, an α-helix structure AMP, shown a broad and strong ability in anti-MDR bacterial infection in vitro and in vivo. Pretreatment with *Cathelicidin-BF* significantly recruit neutrophils and macrophage to the lung and induce neutrophil extracellular traps formation which reduced bacterial burden and improve mice survival[@CIT0008] LL-37 regulates the differentiation and phagocytosis of DC cells which is dependent on overexpression of phagocytosis receptor and costimulatory molecule CD86\\CD80\\CD40[@CIT0022] Whether *Tachyplesin III* mediate innate immune cells especially monocytes remains unclear, we doubt that *Tachyplesin III* could remarkably increase mice against MDR bacterial infection by the directly killing mechanism collaboration with regulate innate immune cells infiltration to the infection site. Thus, it is essential to evaluate the ability of *Tachyplesin III* to achieve mixed bacterial clearance in vivo. Herein, we identified a potential role for the AMP *Tachyplesin III* in host defense against *P. aeruginosa and A. baumannii* coinfection.

Materials and methods {#S0002}
=====================

Ethics statement {#S0002-S2001}
----------------

The animal experiments were approved by the Ethics Committee of Animal Care and Welfare of the Institute of Medical Biology, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) (Permit Number: SYXK (dian) 2010-0007) in accordance with the animal ethics guidelines of the Chinese National Health and Medical Research Council (NHMRC) and the Office of Laboratory Animal Management of Yunnan Province, China. All efforts were made to minimize animal.

Cell culture and treatment {#S0002-S2002}
--------------------------

MH-S (mouse alveolar macrophage), which was purchased from Chinese Academy of Sciences cell bank, was cultured in RPMI 1640 medium containing 10% FBS, 1% penicillin--streptomycin, 1% nonessential amino acids, and 1% L-glutamine (Solarbio^®^ Life Science). Cells were seeded onto 12-well plates at a million cells per well and incubated overnight. One hour before *Tachyplesin III* (Southeast Asian horseshoe crab, KWCFRVCYRGICYRKCR-NH2, Sangon^®^ Biotech, China) treatment, the cells were washed three times with PBS, incubated with fresh RPMI 1640 medium without antibiotics, and then treated with *Tachyplesin III* at concentrations of 0 µg/mL, 10 µg/mL, and 100 µg/mL for 3 hrs. *Tachyplesin III* was resuspended in fresh RPMI 1640 medium.

Neutral red phagocytosis {#S0002-S2003}
------------------------

Briefly, after pretreatment with *Tachyplesin III*, MH-S cells were washed three times with PBS before neutral red staining. Next, 500 µL fresh RPMI 1640 medium containing 0.05% neutral red medium that was filtered with a 0.22 µm filter was added to the 12-well plates and incubated for 4 mins. After removing the medium and washing the cells three times with PBS, multiple red bubbles could be observed inside the treated cells under a microscope (Nikon, Japan). Acid-ethanol solution consisting of 50% ethanol, 1% acetic acid, and 49% ddH~2~O was subsequently used for neutral red extraction. Finally, the results were determined by absorbance measurements with a NanoDrop 2000 at 540 nm, which is the absorption peak for neutral red solution. The peptide Cramp (GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ) was employed as control peptide.

Animals {#S0002-S2004}
-------

Six- to eight-week-old female *BALB/c* mice were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd. and maintained in the Central Animal Care Services of our institute under specific pathogen-free (SPF) conditions.

Bacterial strains and infection of mice {#S0002-S2005}
---------------------------------------

Two MDR clinical isolates that were inventory from our own laboratory, *P. aeruginosa* 1409 and *A. baumannii* 1408, were identified with a Vitek 32 system (bioMerieux, France) and further verified by 16S rDNA sequencing with the universal primers 27f and 1492R as previously described[@CIT0004] Both *P. aeruginosa* 1409 and *A. baumannii* 1408 were grown overnight with shaking in Luria-Bertani (LB) medium at 37°C and then subcultured with fresh LB medium for 4 hrs. When the bacterial concentration corresponding to an OD600 value reached 0.5, the culture was centrifuged at 5000× g for 10 mins, and the bacteria were washed twice with PBS (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na~2~HPO~4~, 0.24 g/L KH~2~PO~4~, pH 7.4) and then resuspended in PBS.

Bacterial infection of mice and survival {#S0002-S2006}
----------------------------------------

To establish the murine bacteremia model, mice were intranasally injected with a 50 µL total volume bacterial solution. For *P. aeruginosa* mono-infection group, 2.5×10^6^ CFU bacterial were used for mice challenge. For *A. baumannii* mono-infection group, 1.5×10^8^ CFU bacterial were used for mice challenge. For coinfection group 2.5×10^6^ CFU *P. aeruginosa* plus 1.5×10^8^ CFU *A. baumannii* were used for mice challenge. To generate *P. aeruginosa plus S. aureus* co-infection model, mice were also intranasally injected with a 50 µL total volume bacterial solution. A lethal dose of *P. aeruginosa* which contains 5×10^6^ CFU bacterial were used for mice challenge. For sub-lethal *P. aeruginosa* mono-infection group, 2.5×10^6^ CFU bacterial were used for mice challenge. A total of 1.5×10^9^ CFU and 7.5×10^8^ CFU *S. aureus* were used for mono-infection group, respectively. For coinfection group, 2.5×10^6^ CFU *P. aeruginosa* plus 7.5×10^8^ CFU *S. aureus* were used for mice challenge. After bacterial challenge, mice survival rate was determined by continuous monitoring for 7 days, which was considered the experiment endpoint, and then all living animals were euthanized.

BALF bacterial burden {#S0002-S2007}
---------------------

To evaluate the BALF bacterial burden, mice were sacrificed 24 hrs after treatment. One milliliter fresh PBS was injected to the lung via minimally invasive tracheostomy, and then repeated lavage of lung tissues for three times. BALF bacterial burden was measured with a 10-fold dilution on LB plates, which were incubated at 37°C overnight. The next day, the CFU was counted, and 30\~300 spots/plate were selected for statistical analysis and expressed as CFU/mL BALF.

Cytokine and chemokine measurements {#S0002-S2008}
-----------------------------------

The BALF extraction supernatants were analyzed for Il-6, TNF-α, MCP-1 (eBioscience), IL-1β, and MIP-2 (Abcam) concentration by an enzyme-linked immune sorbent assay (ELISA) kit following the manufacturer's instructions[@CIT0016]

Lung histological analysis {#S0002-S2009}
--------------------------

The lung tissue histology analysis was performed as previously described[@CIT0035] Briefly, the left lung tissues were harvested from mice the day after bacterial infection and fixed in 4% paraformaldehyde at room temperature for 24 hrs. Subsequently, the tissues were embedded in paraffin and stained with a hematoxylin and eosin (H & E) kit purchased from Solarbio^®^ Life Science.

Statistical analysis {#S0002-S2010}
--------------------

All data were analyzed using GraphPad Prism 7.0 and presented as the mean±standard deviation (SD). The nonparametric log-rank test was used for survival rate comparisons, and the other comparisons were performed using Student's *t*-test or one-way ANOVA between two or three groups, respectively. \*indicates *P*-value\<0.05, \*\*indicates *P*-value\<0.01, \*\*\*indicates *P*-value\<0.001.

Results {#S0003}
=======

Mixed infection with *P*. *aeruginosa* and other bacteria reduces mouse survival {#S0003-S2001}
--------------------------------------------------------------------------------

To identify the damage of *P. aeruginosa* and *A. baumannii* mixed infection in vivo, we mimicked the pathogenic pattern of these two MDR bacteria. Therefore, three infected BALB/c mouse groups, representing *P. aeruginosa* and *A. baumannii* single and mixed infections, containing eight mice per group, were employed. The mixed-infection mouse group were intranasally infected with a 50 µL total volume of mixed bacteria consisting of 2.5×10^6^ CFU of live *P. aeruginosa* and 1.5×10^8^ CFU of live *A. baumannii*; the same doses were used in the single infection groups. Although the mice were coinfected with sub-lethal doses of bacteria, fewer than 40% of the mice survived to the 7-day study endpoint in the coinfection group, whereas only one *P. aeruginosa-*infected mouse died (*P*\<0.05), and none of the *A. baumannii*-infected mice died (*P*\<0.01) ([Figure 1](#F0001){ref-type="fig"}). To investigate whether *P. aeruginosa* could potentiate Gram-positive bacterial infections, mice were intranasally infected with *P. aeruginosa in* combination with *S. aureus*. As expected, most animals died in the coinfection group ([[Figure S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=217020.pdf)), which is consistent with recent studies.[@CIT0007],[@CIT0023] Our data indicate that compared with single infection, mixed bacterial infection with *P. aeruginosa* and Gram-negative *A. baumannii* or gram-positive *S. aureus* significantly reduced the survival rate.Figure 1Coinfection of *P. aeruginosa* and *A. baumannii* reduces mouse survival. Survival curve of *BALB/c* mice (n=8) infected with *P. aeruginosa* (2.5×10^6^ CFU) (Pa) alone, *A. baumannii* (1.5×10^8^ CFU) (Aba) alone, or *P. aeruginosa*+*A. baumannii*. Survival rates were monitored daily for a week, and survival rate significance was determined by log-rank test. \**P*\<0.05 compared to mono-*P. aeruginosa* infection, \*\**P*\<0.01 compared to *A. baumannii* mono-infection, and data represent at least three trials. The animals were euthanized the day after observation endpoint.

Coinfection of *P*. *aeruginosa* and *A. baumannii* causes serious disease {#S0003-S2002}
--------------------------------------------------------------------------

Gram-negative bacterial pathogen infection can trigger a robust systemic response of pro-inflammatory cytokines and chemokines[@CIT0024] To investigate the pathogenic inflammatory reaction caused by bacterial infection, we first detected the levels of pro-inflammatory cytokines and chemokines in BALF collected at 24 hrs after bacterial infection. During *P. aeruginosa* and/or *A. baumannii* infection, the expression of IL-1β, IL-6, TNF-α, MIP-2, and MCP-1 was significantly induced in the infection groups compared with the control (Ctrl) groups. The production of cytokine IL-1β and chemokine MCP-1 in the mixed-infection group was significantly higher than that in the mono-infection groups. Interestingly, there were no differences in IL-6, TNF-α, and MIP-2 production between the *P. aeruginosa* plus *A. baumannii* mixed-infection group and the *P. aeruginosa* mono-infection group, but the expression of IL-6 and TNF-α in the mixed-infection group was higher than that in the *A. baumannii* mono-infection group ([Figure 2A](#F0002){ref-type="fig"}). Histological analysis show that, in contrast to WT mice, bacterial infection induced histological lung injury and the coinfection group presented the most serious injury. Increased vascular leakage and bleeding, inflammatory cell infiltration and alveolar disruption occurred in the single-bacterial infection group, and this condition was worse in the mixed-infection group ([Figure 2B](#F0002){ref-type="fig"}). In line with these results, the H & E score also consist with pathological section results ([Figure 2C](#F0002){ref-type="fig"}). In summary, our results demonstrate that pro-inflammatory cytokine IL-1β and chemokine MCP-1 were significantly increased and lung injury was significantly increased in the coinfection group.Figure 2Bacterial coinfection induced more cytokines production in BALF and worse lung injury in vivo than mono-infection. (**A**) Mice were intranasally infected with co- and mono-bacterial solutions, and BALF was collected in 1 mL cold phosphate buffer saline (PBS) at 24 hrs after injection. BALF was collected after inoculation, and the levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and chemokines MIP-2 and MCP-1 were determined by ELISA. Coinfection enhanced cytokine and chemokine production. Bars represent the mean±SEM for six mice. (**B**) Hematoxylin-eosin (H & E) staining of the lung tissues from mice at 24 hrs after infection. Representative sections of control mice and mono- and co-infected mice are shown. Obvious bleeding and inflammatory cell infiltration were observed, indicating that bacterial coinfection enhances worse lung injury in vivo. (**C**) H & E pathological score results are shown as histograms. The data are shown as the mean±SEM. Comparisons among two groups were calculated using paired *t*-test and one-way ANOVA for three or more groups (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001).**Abbreviation:** ns, no significance.

Pretreatment with *Tachyplesin III* protects mice against mixed bacterial infection {#S0003-S2003}
-----------------------------------------------------------------------------------

*Tachyplesin III* is cytotoxic to mammalian cells and shows MDR bacterial-killing activity[@CIT0019] To test the toxicity of *Tachyplesin III* in vivo, the mice were intravenously (i.v.) injected with a 5, 10, and 20 mg/kg gradient peptide dose. Only one mouse in the 20 mg/kg group died, and none of the mice in the 5 and 10 mg/kg dose groups died ([Figure 3A](#F0003){ref-type="fig"}). The 10 mg/kg dose was chosen for the infection study. First, we try a therapeutic plan to i.v. inject with 10 mg/kg *Tachyplesin III* and control peptide *Cathelicidin-BF* 2 hrs after lethal dose of *P. aeruginosa* infection, *Cathelicidin-BF* significantly increased the survival rate as we described earlier, but *Tachyplesin III* did not show any potential activity in vivo ([[Figure S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=217020.pdf)). Then, BALB/c mice were treated (i.v.) with a single dose of 10 mg/kg *Tachyplesin III*, and *Meropenem* was used as a control. Both *P. aeruginosa* and *A. baumannii* were intranasally injected 24 hrs after peptide inoculation. As expected, no deaths occurred within 24 hrs after peptide and bacterial inoculation. Strikingly, in the preventive treatment condition, the mortality rate was significantly reduced within a week in the *Tachyplesin III* peptide-treated group but not in the *Meropenem*-treated group ([Figure 3B](#F0003){ref-type="fig"}). To further investigate the pivotal role of *Tachyplesin III* in the coinfection model, the bacterial burden in BALF was measured at 24 hrs after infection. As expected, the bacterial loads in the *Tachyplesin III* peptide-treated group were significantly lower than those in the model and control groups ([Figure 3C](#F0003){ref-type="fig"}). Taken together, our findings strongly suggest a potential role for *Tachyplesin III* in triggering an antimicrobial response against mixed bacterial infection, reducing the bacterial burden in lung tissues and improving survival.Figure 3Protective efficacy of *Tachyplesin III* therapy in a mixed bacterial infection murine model of pneumonia. (**A**) Survival curve of *BALB/c* mice (n=6) intravenously infected with *Tachyplesin III* at different doses of 5, 10, and 20 mg/kg. Only one mouse died in the 20 mg/kg group, and no mice died in the 5, 10 mg/kg group, indicating that *Tachyplesin III* was safe through intravenous injection at 10 mg/kg. (**B**) The therapeutic potential of *Tachyplesin III* in bacterial coinfection pneumonia. Pretreatment with 10 mg/kg *Tachyplesin III* significantly increased the mouse survival rate compared with that of the model group, while meropenem-treated mice had no effect on MDR bacterial infection. (**C**) BALF bacterial burden in the bacterial coinfection group. Viable bacteria in the BALF that were collected at 24 hrs after bacterial infection were decreased in the pretreatment with *Tachyplesin III* group compared with the non-treatment (Model) and *Meropenem*-treated (Ctrl) groups. Bars represent the mean±SEM, survival rates were monitored daily for a week, and survival rate significance was determined by log-rank test, \**P*\<0.05; BALF comparisons among two groups were calculated using paired *t*-test and one-way ANOVA for three or more groups (\**P*\<0.05, \*\**P*\<0.01). The animals were euthanized the day after observation endpoint.

*Tachyplesin III* reduces pro-inflammatory cytokines and chemokines production and ameliorates tissue damage in vivo {#S0003-S2004}
--------------------------------------------------------------------------------------------------------------------

To determine whether *Tachyplesin III* reduces the systemic response of pro-inflammatory cytokines induced by the mixed bacterial infection with *P. aeruginosa* plus *A. baumannii*, the level of serum cytokines and chemokines was measured. As expected, *Tachyplesin III* therapy reduced the production of pro-inflammatory cytokines as IL-1β, IL-6, and TNF-α, but there was no difference in the production of chemokine MCP-1 and MIP-2 ([Figure 4A](#F0004){ref-type="fig"}). Histological examination showed no difference between the *Tachyplesin III* group and the wild-type group, which indicated that injection (i.v.) with 10 mg/kg *Tachyplesin III* did not obviously cause lung injury ([Figure 4B](#F0004){ref-type="fig"}). Treatment with *Tachyplesin III* resulted in decreased inflammatory cell infiltration, vascular leakage, and alveolar disruption compared with those in the coinfected groups or in the *Meropenem*-treated group ([Figure 4B](#F0004){ref-type="fig"}). In line with these results, the H & E score also consist with pathological section results ([Figure 4C](#F0004){ref-type="fig"}). Collectively, these data indicated that *Tachyplesin III* plays a crucial role in the prophylaxis of MDR bacterial mixed infection-induced lung injury and inflammatory cytokine production.Figure 4Pulmonary pathological changes of *Tachyplesin III*-treated mice. (**A**) Cytokine and chemokine production was reduced in *Tachyplesin III*-pretreated mice. Serum was collected 24 hrs after bacterial infection, and IL-1β, IL-6, TNF-α, MIP-2, and MCP-1 were identified by ELISA. (**B**) Lung tissue was stained with H & E, no significant tissue damage occurred in *Tachyplesin III* (10 mg/kg), and less bleeding and inflammatory immune cell infiltration occurred in *Tachyplesin III*-treated mice than in the model and control groups. (**C**) H & E pathology was scored blindly in mouse lungs after infection with *P. aeruginosa* and *A. baumannii*. The data are shown as the mean±SEM. Serum cytokine and lung pathology score comparisons among the two groups were calculated using paired *t*-test and one-way ANOVA for three or more groups (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001).

*Tachyplesin III* enhances the phagocytic function of mouse alveolar macrophages {#S0003-S2005}
--------------------------------------------------------------------------------

Macrophage phagocytosis, which is a secondary line of defense line in host innate immunity against bacterial infection, plays an important role in bacterial clearance[@CIT0025] To evaluate the effect of *Tachyplesin III* on macrophage phagocytosis, we treated the mouse alveolar macrophage cell line MH-S with different *Tachyplesin III* concentrations in vitro. After MH-S cells were exposed to *Tachyplesin III* for 3 hrs, a significant dose-dependent phagocytosis of neutral red was observed ([Figure 5A](#F0005){ref-type="fig"}). In addition, after extracting the neutral red from MH-S cells, the concentration of neutral red was significantly increased in *Tachyplesin III*-treated cells than that in control peptide- (Cramp) treated cells ([Figure 5B](#F0005){ref-type="fig"}). Macrophage phagocytosis was increased in a dose-dependent manner ([Figure 5C](#F0005){ref-type="fig"}). Altogether, these results indicated that *Tachyplesin III* induced obvious alveolar macrophage phagocytosis.Figure 5*Tachyplesin III* enhanced the phagocytosis of mouse alveolar macrophages in vitro. (**A**) Bright-field image showing neutral red phagocytosis of MH-S cells in a dose-dependent manner with *Tachyplesin III* treatment. (**B**) Quantification of phagocytic capacity via the OD~540~ nm measurement value of neutral red extract. (**C**) MH-S cells were incubated with *Tachyplesin III* and control peptides. The levels of neutral red phagocytosis were measured by OD~540~ nm detection. The data are shown as the mean±SD, and comparisons among two groups were calculated using paired *t*-tests and one-way ANOVA for three or more groups (\**P*\<0.05, \*\**P*\<0.01).

Discussion {#S0004}
==========

For nearly 40 years, no novel antibiotics have been discovered or developed, while multiple natural substances, such as AMPs, have recently been described[@CIT0001] However, the entire process from identifying to refining antimicrobial products, which are urgently needed for contemporary clinical therapy, is slow and time-consuming, although several representative AMPs, such P-113, MSI-78, MBI-226, IB-367, and rBPI21, have been applied in clinical trials.[@CIT0026],[@CIT0027],[@CIT0028] According to a report by the World Health Organization (WHO), the use of antibiotics extends the human life span at least 20 years. Nevertheless, this protective effect is becoming increasingly weaker with bacterial evolution, particularly the emergence and spread of MDR bacteria, which may contribute to 30 million deaths by 2050[@CIT0029]

Clinically, the Gram-positive bacterium *S. aureus* is often observed in coinfections with gram-negative bacteria, including *P. aeruginosa, K. pneumoniae,* and *A. baumannii*, which depend on the influence of toxins on mucosal host defense[@CIT0007] Carbapenem-resistant (CSE) *A. baumannii* and *P. aeruginosa*, two Gram-negative bacteria, are the most critical global priority opportunistic pathogens. In the clinic, *P. aeruginosa* plus *A. baumannii* is the most common and dangerous combination[@CIT0030] and a critical contributor to the morbidity and mortality of long-term in-hospital respiratory medicine patients, particularly VAP patients.[@CIT0005],[@CIT0006] Our study revealed that compared with monoinfection, coinfection with *P. aeruginosa* plus *A. baumannii* significantly reduced mouse survival, and only one mouse dead with *P*. aeruginosa infection alone ([Figure 1A](#F0001){ref-type="fig"}). Interestingly, none of the mice intranasally infected with 1.5×10^8^ CFU live *A. baumannii* died, whereas the addition of less than 3×10^6^ CFU *P. aeruginosa* significantly reduced the survival rate, suggesting that the synergistic interactions of these bacteria increased disease severity, which coincides with the clinical phenomenon.[@CIT0031] Therefore, this lethal pneumonia model was further analyzed. Gram-negative bacterial pathogen infections can trigger a robust systemic response of pro-inflammatory cytokines and chemokines[@CIT0032] In the current study, we indicated that, in the case of mixed bacterial infection, the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, known as a "cytokine storm", were significantly increased compared with those in the single-bacterial infection group, which may be the main cause of multiple organ failure or death. Furthermore, MDR bacterial coinfection induced worse lung injury as well as multiple inflammatory cell infiltration, alveolar disruption, and vascular leakage ([Figure 2](#F0002){ref-type="fig"}).

Our previous work demonstrated that *Tachyplesin III* provides an antibacterial effect against MDR bacteria in vitro[@CIT0033] which may present strong anti-MDR bacteria activity by interacting with FabG to trigger bacterial death[@CIT0009] and this treatment is hypothesized to provide bacterial clearance in vivo. Therefore, to further examine the influence of *Tachyplesin III* on mixed bacterial infection, we proposed a murine pneumonia model that enabled us to evaluate *Tachyplesin III* activity in vivo. Herein, we found that although *Tachyplesin III* showed cytotoxicity to mammalian cells in vivo, no animal death or lung injury occurred in mice injected (i.v.) with a 10 mg/kg dose ([Figures 3A](#F0003){ref-type="fig"} and [4A](#F0004){ref-type="fig"}--E). Strangely, we found that *Tachyplesin III* i.v. injection had non-therapeutic effect in the lethal dose of *P. aeruginosa* challenge ([[Figure S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=217020.pdf)) which reminds us that future research should focus on the development of detoxified form of *Tachyplesin III*. In a murine pneumonia model, a low lethal dose of *P. aeruginosa* significantly reduced the survival rate of *A. baumannii-*infected and *S. aureus*-infected mice ([[Figure S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=217020.pdf)), which was prevented by pretreatment with *Tachyplesin III* ([Figure 3B](#F0003){ref-type="fig"}). Consistent with the reduced mortality, pretreatment with *Tachyplesin III* significantly reduced the BALF bacterial burden, decreased the cytokine storm, and reduced lung injury, which may be the main causes of animal death ([Figures 3B](#F0003){ref-type="fig"} and [4A](#F0004){ref-type="fig"}--[C](#F0004){ref-type="fig"}). Compared with mono-infections, mixed infections with *P. aeruginosa and A. baumannii* trigger even more serious disease in vivo.

Alveolar macrophages and neutrophils are the first immune cells in the host innate response to bacterial pathogen infection[@CIT0034] Our recent work indicated that *Cathelicidin-BF*, another AMP subtype, enhanced neutrophil extracellular traps, which are the main facilitators of the capture and clearance of bacteria through the activation of innate immunity[@CIT0035] Other studies have indicated that macrophages also contribute to the clearance of bacterial pathogen infection[@CIT0036] In this study, our results demonstrated that *Tachyplesin III* improved alveolar macrophage phagocytosis in a dose-dependent manner in vitro ([Figure 5](#F0005){ref-type="fig"}), which may directly reduce the BALF burden ([Figure 3C](#F0003){ref-type="fig"}). Thus, our study reports a novel therapeutic strategy for gram-negative MDR bacterial coinfection using the AMP *Tachyplesin III*.

Taken together, the present work illustrated that coinfection with *P. aeruginosa* plus *A. baumannii* causes more serious disease than individual bacterial infections, especially by the release of pro-inflammatory cytokine IL-1β and a decrease in immune cell infiltration, thereby triggering lung injury. Dramatically, the prophylactic capability of *Tachyplesin III* against clinical MDR bacterial isotype infection was identified. This phenomenon could be partially explained by significantly enhanced survival, reduced BALF bacterial burden, decreased pro-inflammatory cytokine and chemokine levels, and reduced lung injury. Simultaneously, the phagocytic function of macrophages was significantly increased under *Tachyplesin III* in vitro.

Conclusion {#S0005}
==========

In conclusion, our findings indicate that the AMP *Tachyplesin III* plays a potential role against MDR bacterial coinfection in vivo. Pretreatment with *Tachyplesin III* ameliorates bacterial coinfection in mice by enhancing macrophage phagocytosis and reducing the production of pro-inflammatory cytokines. Our results highlight the importance of external AMPs against MDR bacterial mixed infection and present a possible therapeutic strategy for controlling multiple bacterial coinfections that should be confirmed in clinical studies.
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